Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025

Nurix Therapeutics, Inc.

Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.
Phase 1b randomized comparison: 600mg RP2D showed 83.3% ORR vs 73.7% for 200mg; PFS trend favoring 600mg.
WM (n=28 evaluable) ORR 75.0% including 10.7% VGPR; median follow-up 8.1 months, median DOR and PFS not reached.
Safety: well tolerated across doses; no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.
Pivotal Phase 2 DAYBreak-CLL-201 enrolling globally; 600mg RP2D selected for further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.